\
&
Contact us
\
&
Contact us
Published on | 1 month ago
Programmes Agro-Food, EnvironmentThe European Commission has opened the CBE JU 2025 call. A total of €172 million will be dedicated to advancing competitive circular bio-based industries in Europe across 13 topics.
The objective of this call is to support the scaling up of technologies leading to industrial deployment and thus boosting investment and job creation, both regional and local.
This call will fund three types of actions:
All stakeholders of the circular bio-based sector can apply before the deadline of 18 September 2025, 17:00 Brussels time.
More information can be found here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health Culture and society Security Digital, Industry & Space
The open and forthcoming calls under Horizon Europe have been published on the Funding & Tenders Portal (Funding - Call for proposals) However, there are technical issues with the filter functions in Pillar 2: filtering per cluster does not display all 2025 call topics within this cluster and advertise call topics of other work programmes. The... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
